|
| Wednesday, 6 April 2005: 4:00 PM-7:00 PM |
| Exhibit Hall C (Marriott Wardman Park Hotel) |
| Poster Abstracts: Osteoporosis - Treatment |
|
| | PTH(1-84) Prevents Vertebral Fractures in Postmenopausal Women With Higher Fracture Risk: Results From the TOP Study
Paul D. Miller, MD, Susan Greenspan, MD |
| | PTH(1-34) stimulates Spine Fusion
Joseph M. Lane, MD, Susan V. Bukata, Emre Tomin, Brett Shore, Matthew Cunningham |
| | Vertebral Height Restoration in Osteoporotic Compression Fractures - Kyphoplasty is Five-Fold Superior to Vertebroplasty Posture Correction
Joseph M. Lane, MD, Michael K. Shindle, MD, Jason Koob, BA, Jonathan A. Cabin, BA, Margaret Peterson, PhD, Susan Bukata, MD |
| | Treatment of Postmenopausal Osteoporotic Women With Parathyroid Hormone(1-84) for 18 Months Improves Trabecular Bone Architecture: A Study of Iliac Crest Biopsies Using Micro-Computed Tomography
DW Dempster, PhD, IA Moreau, DVM, MSc, A Varela, DVM, MSc, SY Smith, MSc, L.-G. Ste-Marie, MD, J Fox, PhD, MK Newman, MS, RR Recker, MD |
| | Does BMD after 5 years of alendronate use predict effects of continued alendronate use?
A.V. Schwartz, PhD, A. Lombardi, MD, J.A. Cauley, Dr.PH, K.E. Ensrud, MD, D.C. Bauer, MD, R.B. Wallace, MD, S.R. Cummings, MD, D.M. Black, PhD |
| | Underuse of osteoporosis treatment in postmenopausal women at high risk for fracture differs by age and ethnicity: Observations from the National Osteoporosis Risk Assessment
Thomas W. Weiss, DrPH, Ethel S. Siris, MD, Susan K. Brenneman, PhD, Paul D. Miller, MD, Ya-Ting Chen, PhD |
| | Comparison of Once-weekly Alendronate and Once-weekly Risedronate in the Osteoporotic Subgroup from the FACT Study
Sydney Bonnick, MD, Marc Hochberg, MD, MPH, Susan Broy, MD, Erluo Chen, MD, MPH, Richard A. Petruschke, PharmD, Anne E. de Papp, MD |
| | Assessment of Adherence and Persistence with Daily and Weekly Dosing Regimens of Oral Bisphosphonates
S J Boccuzzi, PhD, S H Folz, PhD, MA Omar, PhD, KH Kahler, SM |
| | Adherence and Persistence Associated with the Pharmacologic Treatment of Osteoporosis
SJ Boccuzzi, SH Folz, MA Omar, KH Kahler, B Gutierrez |
| | Medication burden among women with postmenopausal osteoporosis
Deborah T. Gold, PhD, Mark E. Ettinger, M.D., F.A.C.R., Rich Gallagher, MBA, Mayur M. Amonkar, PhD, Sydney Lou Bonnick, M.D., F.A.C.P. |
| | Treatment persistence is improved with once-weekly versus once-daily bisphosphonate therapy, but remains suboptimal
Deborah T. Gold, PhD, James A. Simon, M.D., Mayur M. Amonkar, PhD, Stuart L. Silverman, M.D.F.A. |
| | Intravenous ibandronate injections with extended dosing intervals provide at least equivalent efficacy to daily oral ibandronate: 1-year results from the DIVA study
Michael A. Bolognese, M.D., Roberto Civitelli, M.D., Marc Drezner, M.D., Ronald Emkey, M.D. |
| | Alendronate Effects in Children with Osteoporosis
Craig B. Langman, MD, Abigail Arwady, Heather Price, MS |
| | Preferential Effect of Salmon Calcitonin Nasal Spray (CT-NS) on Lumbar Spine Vertebral Compression Fracture (VCF) in Elderly Osteoporotic Women: Results from the Proof Study
Stuart L. Silverman, MD, FACP, FACR, Melvin Olson, Ph.D, Linda Mindeholm, MD, Moise Azria, PhD, Charles Chesnut, MD |
| | Comparison of Overall and Upper Gastrointestinal Tolerability of Once-Weekly Alendronate and Risedronate Across Age Subgroups: Results from the FACT Study
S. Broy, MD, K. Saag, MD, M. Hochberg, MD, MPH, N. Binkley, MD, E. Chen, MD, MPH, C. Skalky, BS, R. Petruschke, PharmD, A.E. de Papp, MD |
| | Sustained Reduction of Vertebral Fracture Risk in the Year after Discontinuation of Risedronate Treatment
Nelson B. Watts, M.D., Ian Barton, BSc, Wojciech P. Olszynski, M.D., Ph.D., Clark D. McKeever, M.D., Michael R. McClung, M.D., Andreas Grauer, M.D., Ph.D. |
| | Racial Disparity in Treatment of Osteoporosis after Diagnosis
Irene Hamrick, MD, Lauren M. Whetstone, Doyle M. Cummings |
| | Raloxifene therapy decreases the risk of new clinical vertebral fractures at 6 months
Yongming Qu, PhD, Mayme Wong, PhD, John L. Stock, MD |
| | A 5 Year Randomized Trial of the Long-term Efficacy and Safety of Alendronate: the FIT Long-term EXtension (FLEX)
D.M. Black, A.V. Schwartz, K.E. Ensrud, A. Rybak-Feiglin, J. Gupta, A. Lombardi, R.B. Wallace, S. Levis, S. Quandt, S. Satterfield, J.A. Cauley, S.R. Cummings |
